Uridine Triacetate Approved by FDA to Deter Chemo Overdose and Toxicities

chemotherapy overdose treatment

Richard Pazdur, MD

Uridine triacetate (Vistogard) has been given a green light by the FDA to treat adult and pediatric patients who have severe or life-threatening toxicities within 4 days of treatment following an overdose of 5-fluorouracil (5-FU) or capecitabine.

The decision was based on two open-label clinical studies that measured 30-day survival rates of adult and pediatric patients who either overdosed on treatment or were experiencing early-onset toxicities. Of those who overdosed, 97% treated with uridine triacetate were still alive after 30 days, and 89% were alive at 30 days when treated for toxicities.

“Treating cancer requires not only selecting which drug may be most effective and well tolerated, but ensuring the correct dose is given at proper intervals. While rare, unintentional overdose can occur,” Richard Pazdur, MD, director, Office of Hematology and Oncology Products, FDA Center for Drug Evaluation and Research, said in a statement.

“Today’s approval is a first-of-its-kind therapy that can potentially save lives following overdose or life-threatening toxicity from these chemotherapy agents.”

Developed by Wellstat Therapeutics, the oral agent uridine triacetate blocks cell damage and death caused by 5-FU and should be taken soon after overexposure—regardless of whether symptoms are present—or early onset of severe toxicities, including severe mucositis, fever, diarrhea, or rash.

Uridine triacetate was tested on 135 adult and pediatric patients in two separate trials who had either overdosed on 5-FU or capecitabine or experienced unusual, life-threatening adverse events within 4 days of receiving 5-FU infusion therapy. The FDA noted that the agent’s safety and efficacy has not been evaluated when treatment is initiated more than 96 hours following chemotherapy administration.

The study measured overall survival at 30 days after taking uridine triacetate, as well as resumption of chemotherapy within the 30 days.

In addition to a 97% survival rate in the overdose group and 89% in the toxicity group, both trials showed that 33% of patients resumed chemotherapy within 30 days of being treated with uridine triacetate.

The agent’s approval is for emergency reactions only following 5-FU or capecitabine, because it can lessen the efficacy of the drugs in non-emergent situations.

Adverse events occurring in more than 2% of patients receiving uridine triacetate included vomiting (10%), nausea (5%), and diarrhea (3%).

The FDA had granted uridine triacetate priority review and fast-track designations to expedite the review and approval of the drug. It has now been granted orphan drug designation, which is intended to expedite the development of the drug by providing incentives such as clinical trial tax credits, user fee waivers, and eligibility for market exclusivity.